ArticleAnalytical and bioanalytical chemistry2026
Spatial localization and pharmacodynamic assessment of intracrine androgen metabolism in CRPC xenograft tumor tissues upon active vitamin D treatment.
Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Castrate-resistant prostate cancer (CRPC) progression is driven by intracrine androgen synthesis despite low circulating androgens. This study investigates the effects of active vitamin D (1,25-(OH)₂-D₃) on intracrine steroidogenesis in LNCaP xenograft tumors. Using mass spectrometry imaging, quantitative LC-MS/MS, and gene expression analyses, we demonstrate that vitamin D modulates androgen metabolism, reducing levels of potent androgen receptor ligands such as testosterone and dihydrotestosterone, while increasing hydroxylated androgen metabolites. Vitamin D treatment also suppresses AR-regulated gene expression and slows tumor growth compared to androgen precursor (DHEA) administration alone. Mass spectrometry imaging revealed widespread intracrine androgen production without distinct spatial localization within tumors at the image resolution analyzed. These findings suggest vitamin D disrupts androgen receptor signaling by altering intracrine androgen biosynthesis, supporting its potential as an adjunct therapy in CRPC management.
Indexed as
Identifiers
41826509What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.